Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 13, 2026

Can Strong iPhone and Mac Portfolio Help Apple Stock Recover in FY26?

View original at finance.yahoo.com
Can Strong iPhone and Mac Portfolio Help Apple Stock Recover in FY26? Apple AAPL shares have dropped 4.2% year to date (YTD), outperforming close peers such as HP HPQ and Microsoft MSFT but lagging Amazon AMZN…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Zacks Consensus Estimate for Apple's fiscal 2026 revenues is pegged at $461.68 billion, indicating 10.94% growth over fiscal 2025

    60% confidence

  • Apple shares are overvalued, as suggested by a Value Score of F

    60% confidence

  • Global smartphone shipments declined 6% year over year in the first quarter of 2026, with Apple leading with 21% market share and shipments growing 5% year over year, driven by strong iPhone 17 demand and improved performance in China

    60% confidence

  • The Zacks Consensus Estimate for Apple's fiscal 2026 earnings is $8.40 per share, indicating 12.6% growth from fiscal 2025

    60% confidence

  • Worldwide PC shipments totaled 62.8 million units in the first quarter of 2026, up 4% year over year

    60% confidence

  • Samsung's shipments declined 6% year over year with 20% market share

    60% confidence

  • Lenovo led PC market with 26.5% market share, trailed by HP and Dell Technologies with 19.3% and 16.5%, respectively. Apple had a 10.6% market share

    60% confidence

Data points we hold from this source

HP Inc. · market share19.3 percent
HP Inc. · pe ratio6.37 ratio
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Can Strong iPhone and Mac Portfolio Help Apple Stock Recover in FY26? — Source | Via News | ViaNews EU